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Abstract
Background: Prescribing medicines for older adults in care homes is known to be sub-optimal. Whilst trials testing
interventions to optimise prescribing in this setting have been published, heterogeneity in outcome reporting has
hindered comparison of interventions, thus limiting evidence synthesis. The aim of this study was to develop a core
outcome set (COS), a list of outcomes which should be measured and reported, as a minimum, for all effectiveness
trials involving optimising prescribing in care homes. The COS was developed as part of the Care Homes
Independent Pharmacist Prescribing Study (CHIPPS).
Methods: A long-list of outcomes was identified through a review of published literature and stakeholder input.
Outcomes were reviewed and refined prior to entering a two-round online Delphi exercise and then distributed via
a web link to the CHIPPS Management Team, a multidisciplinary team including pharmacists, doctors and Patient
Public Involvement representatives (amongst others), who comprised the Delphi panel. The Delphi panellists
(n = 19) rated the importance of outcomes on a 9-point Likert scale from 1 (not important) to 9 (critically important).
Consensus for an outcome being included in the COS was defined as ≥70% participants scoring 7–9 and <15%
scoring 1–3. Exclusion was defined as ≥70% scoring 1–3 and <15% 7–9. Individual and group scores were fed back
to participants alongside the second questionnaire round, which included outcomes for which no consensus had
been achieved.
Results: A long-list of 63 potential outcomes was identified. Refinement of this long-list of outcomes resulted in
29 outcomes, which were included in the Delphi questionnaire (round 1). Following both rounds of the Delphi
exercise, 13 outcomes (organised into seven overarching domains: medication appropriateness, adverse drug events,
prescribing errors, falls, quality of life, all-cause mortality and admissions to hospital (and associated costs)) met the
criteria for inclusion in the final COS.
Conclusions: We have developed a COS for effectiveness trials aimed at optimising prescribing in older adults in care
homes using robust methodology. Widespread adoption of this COS will facilitate evidence synthesis between trials.
Future work should focus on evaluating appropriate tools for these key outcomes to further reduce heterogeneity in
outcome measurement in this context.
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Background
There is an increasing need and expectation for
researchers to incorporate and report core outcome sets
(COSs) when conducting and evaluating effectiveness
trials in healthcare [1]. A COS is a list of outcomes
which should be measured and reported, as a minimum,
in all effectiveness trials pertaining to a specific health
area, thereby facilitating comparisons of outcomes be-
tween studies and evidence synthesis [2]. The agreed
COS should have relevance and be informative to policy
makers and stakeholders alike [3]. The relevance of
much well-intentioned and robustly conducted research
is limited by extremely varied choices of outcomes,
thereby impeding understanding, limiting research syn-
thesis [3] and causing ‘avoidable waste’ [2].
The value of health research is greatly increased when
reporting outcomes which are usable, homogeneous and
meaningful, and which are therefore also more easily
accessed by others. In addition to the reporting of numer-
ous and varied outcomes, a lack of standardised outcomes
can lead to reporting bias, i.e. selecting statistically signifi-
cant results only, or reporting sub-sets of results, which
can negatively affect the quality of systematic and meta-
analytic reviews [1, 3, 4]. The reporting of outcomes re-
quires both careful selection and appropriate reporting.
For example, Hirsch and colleagues [5] identified that
more than 25,000 outcomes were reported just once or
twice in oncology trials. Furthermore, the Outcome
Reporting Bias in Trials (ORBIT) study revealed that more
than half of the studies included for review (55%) failed to
report complete results for the primary outcome [6].
Thus, the need to obtain consensus on key outcomes is
considerable and equally urgent.
The impetus to develop coherent COSs for health re-
search to overcome the problems just described above
has largely originated from the COMET (Core Outcome
Measures in Effectiveness Trials, 2010) Initiative.
COMET ‘brings together researchers interested in the
development and application of agreed standardised sets
of outcomes’ [7]. COSs are developed through a variety
of methods, namely semi-structured discussion, unstruc-
tured group discussion, the Delphi technique, Consensus
Development Conferences and surveys [2]. To date,
COSs have been developed for many areas of health re-
search, including prostate cancer [8], HIV/AIDS [9],
lower back pain [10], schizophrenia and bipolar disorder
[11], cardio-thoracic surgery [12], asthma [13] and, more
recently, pain therapy [14] and falls [15], to name some
examples.
The specific focus of this paper is the development of
a COS for trials involving interventions to optimise pre-
scribing in older adults in care homes. Medicines opti-
misation, a term describing the safe and effective use of
medicines, has become a significant global public health
issue [16]. The global population is rapidly ageing, and in
the UK, it has been estimated that almost a quarter of the
population will be aged ≥65 years by 2034 [17]. In the UK,
the prescription of medicines is the most frequent patient-
level healthcare intervention [18], and 60% of all dispensed
medicines are prescribed for those aged ≥60 years [19].
The volume of research focussing on medicines optimisa-
tion is steadily growing, particularly within hospitals, out-
patient settings and primary care [20]. However, there is a
relative lack of research conducted within the care home
setting. In the UK, 3.2% of people aged 65 and older reside
in care homes, and people aged 85 and older represent
nearly 60% of the care home population [21]. Moreover,
prescribing for older people is complex, and most of the
evidence shows that prescribing for older residents in care
homes is sub-optimal [22]. An age-associated reduction in
physiological capacity alongside an increased prevalence
of multimorbidity and polypharmacy contribute to the
complexities of prescribing in older adults [23]. Prescrib-
ing interventions are the most common interventions that
take place in care homes and often target inappropriate
prescribing (under-, over-, or mis-prescribing), adverse
events and compliance [24], and commonly aim to ‘opti-
mise’ the use of medicines.
Some of the factors contributing to all aspects of poor
medicines use in care homes are polypharmacy (care
home residents are prescribed an average of eight medi-
cines), inappropriate prescribing, inadequate communica-
tion and handover protocols between staff, interruptions
during drug rounds, inadequate communication across
the various healthcare interfaces’ and the lack of clear re-
sponsibility for the review of patients’ medicines [24]. To
illustrate further, Loganathan and colleagues’ systematic
review [20] of interventions to optimise prescribing in care
homes reported heterogeneity in outcomes, hindering the
development of firm conclusions and recommendations
for practice. Additionally, a recently published Cochrane
Review conducted by Alldred and colleagues [22] of the
effectiveness of interventions to optimise prescribing for
older people living in care homes found that, whilst there
was some evidence of improvements in medicines opti-
misation as a result of interventions, firm conclusions re-
lating to the overall effectiveness of interventions were
difficult to draw due to, in part, the heterogeneity in out-
comes measured across studies. The overall impact of in-
terventions aimed at optimising prescribing to improve
outcomes for care home residents, therefore, remains un-
clear, and the overall value of research remains limited.
Clearly, a more cohesive and standardised approach is
needed to improve the quality of evidence syntheses to
help develop reliable conclusions which can, in turn, influ-
ence both policy and practice.
The purpose of this paper is to describe the process of
developing a COS for use in effectiveness trials aimed at
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optimising prescribing in older adults in care homes. This
COS was developed within a wider programme of study
— the Care Homes Independent Pharmacist Prescribing
Study (CHIPPS) (https://www.uea.ac.uk/chipps) – a UK
programme grant which incorporates a multicentre
cluster-randomised controlled trial to determine the ef-
fectiveness and cost-effectiveness of pharmacist independ-
ent prescribers taking responsibility for the prescribing of
patients’ medicines in care homes. The scope of the COS
was informed primarily by the needs of the wider CHIPPS
research programme. The aim and scope of the present
study were therefore to develop a COS applicable to ef-
fectiveness trials, involving any intervention type, to target
optimising prescribing in older adults in care homes.
Methods
The study was prospectively registered with the COMET
Initiative (registration number: 843 available online at:
http://www.comet-initiative.org/studies/details/843). De-
velopment of the COS involved two successive phases
which were informed primarily by the published guid-
ance from Williamson et al. [1] on COS development
methodology. The first phase involved generating a
long-list of outcomes for consideration for inclusion in
the COS, through both a review of the published litera-
ture and stakeholder involvement (see below). The sec-
ond phase utilised the Delphi technique [13], in the
form of a web-based questionnaire, to elicit consensus
on the final list of outcomes to be included in the COS.
Phase 1: Generating and refining the long-list of
outcomes
The aim of this phase was to identify potential outcomes
for inclusion in the COS. As such, we sought to identify
only ‘what’ to measure, not ‘how’ outcomes could be
measured (i.e. the identification of different measure-
ment instruments used to measure the same outcome).
To generate the long-list of potential outcomes to be
considered for inclusion in the COS, two parallel
strategies were employed. The first strategy involved
identifying outcomes through a review of the published
literature relating to interventions to optimise prescrib-
ing in care homes. For the purposes and intended scope
of this COS, ‘care homes’ were defined as nursing homes,
residential care homes, skilled-nursing facilities, assisted-
living facilities and aged-care facilities. The studies
included in the recently updated Cochrane Review [22]
of interventions to optimise prescribing in care homes
formed the basis of the review of the relevant literature.
Given the timeliness and relevance of this review, with
regard to the scope of the COS, it was not considered
necessary to extend the literature review further. Twelve
randomised controlled trials were included in the review,
which collectively involved 10,953 older adults (65 years
or older) resident in 355 care homes across ten
countries. Studies included in the review tested the effect
of a range of interventions which aimed to optimise care
home residents’ complete medication regimens. The
review did not include studies evaluating interventions
aimed at specific medicines or medicine classes (e.g.
benzodiazepines) or those concentrating on one health-
care condition. Further details on the literature search
strategy and inclusion criteria have been reported in the
review [22]. Information on every outcome measured
and reported in each of the 12 trials was extracted
verbatim and compiled in data extraction tables.
The second strategy employed was stakeholder
involvement in the form of focus groups and semi-
structured interviews. These were conducted as part of
the wider CHIPPS programme; the primary aim of the
interviews/focus groups was to define the components
of the intervention (i.e. the service specification) in the
CHIPPS trial. Stakeholder participants comprised gen-
eral practitioners (GPs), pharmacists, care home man-
agers, care homes staff and care home residents/
relatives, located in four different sites across the UK.
Recruitment to focus groups was achieved through
several channels, beginning with Principal Investigators
at each of the four sites identifying local gatekeepers for
each stakeholder group. GPs, primary care and commu-
nity pharmacists who had experience working in care
homes were identified and approached via relevant local
networks. Care homes were contacted initially using lists
obtained from the relevant care home regulatory bodies’
websites, and then through existing local research
networks. Participating care home managers then acted
as gatekeepers to facilitate the recruitment of other care
home staff, residents and relatives. Amongst those
stakeholders who expressed an interest in participating,
a purposive sampling approach was followed to maxi-
mise the diversity amongst these interested stakeholders.
This approach helped to ensure a representative mix of
stakeholders from urban and rural locations, multiple
(chain) and independent care homes and large and small
GP practices, for example. Participants unavailable to
attend a stakeholder focus group were invited to partici-
pate in an individual interview. Whilst most of the
topics covered in the interviews/focus groups centred on
the CHIPPS intervention and pharmacist independent
prescriber (PIP) training, participants were also asked
what they viewed as ‘important outcomes to measure in
studies which aimed to determine the effectiveness of
interventions to optimise prescribing in care homes’.
Interviews and focus groups were audio-recorded
and transcribed verbatim. Analysis of the transcripts
was conducted independently by two researchers who
extracted the outcomes proposed by the stakeholders
verbatim.
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Once all outcomes were identified and extracted from
both the literature sources and the stakeholder focus
groups and interviews, the resulting long-list of outcomes
was reviewed and refined. Duplicate items were removed
as were process measures, i.e. outcomes which are simply
a measure of an aspect of the delivery of the intervention.
In order to create a manageable list of outcomes for
consideration in the Delphi exercise (see the following
section), four members of the CHIPPS team (CH, DA, LS
and RH), with expertise in the area (who were excluded
from participation in the Delphi exercise) independently
reviewed the list of outcomes and voted anonymously on
whether they thought each outcome should be included in
or excluded from the Delphi questionnaire. Only those
outcomes which were voted by unanimous decision to be
excluded were subsequently omitted.
Phase 2: Delphi consensus exercise
The second phase of the COS development utilised a
Delphi exercise to achieve consensus across the partici-
pant group on outcomes to be included in the final
COS. The Delphi technique typically involves adminis-
tering a series of rounds of questionnaires with anon-
ymised feedback provided between each round.
As there are currently no guidelines concerning the
ideal number of participants required to form a Delphi
panel for COS development [13], it was decided, a priori,
that the chosen panel would comprise the 19 members
of the wider CHIPPS management team, all of whom
had relevant aged care experience specifically relating to
care homes. Recognising the importance of involving a
wide range of stakeholders, the Delphi panel (n = 19)
therefore was a heterogeneous group that included
academic pharmacists (n = 3), geriatricians (n = 2), Patient
Public Involvement (PPI) representatives (n = 2), health
economists (n = 2), senior CHIPPS research fellows (n = 2),
a prescribing advisor pharmacist (n = 1), an academic
sociologist (n = 1), a research governance manager (n = 1), a
care home quality director (n = 1), an educationalist (n = 1),
an academic doctor (n = 1), a GP (n = 1) and an academic
nurse (n = 1). As the panellists were based in disparate
geographical locations across the UK, an online two-round
Delphi questionnaire was administered to facilitate efficient
data collection.
The refined list of outcomes generated during Phase
1 of the COS development process was used to
construct a list of questionnaire items. At the start of
the questionnaire, panellists were asked to rate how
important they thought it was for each outcome to be
included in a COS for studies involving optimising
prescribing in care homes. Each questionnaire item was
formatted with the outcome set out in bold font, and
with a brief explanation of the outcome provided
underneath, as in this example:
Physical functioning. Explanation: Care home
residents’ physical functioning i.e. ability to perform
physical tasks/everyday abilities (e.g. mobility, using
stairs, dressing oneself, etc.)
The introduction to the questionnaire clarified for
panellists that the ‘explanation’ should not be interpreted
as an all-encompassing definition of the outcome, but
rather as providing context and preventing misinterpret-
ation of the meaning of the outcome terminology.
Panellists were instructed to score the importance of
each outcome on a Likert scale ranging from 1 to 9,
where scores of 1 to 3 indicated an outcome of ‘limited
importance’, 4 to 6 ‘important but not critical’ and 7 to 9
‘critical’. This scoring system has been used widely by
COS developers and is derived from the recommendations
of the Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE) Working Group [25].
Furthermore, panellists were able to select ‘unable to score’
if they felt unable to offer an opinion on a particular
outcome. At the end of the first round of the questionnaire,
panellists were also invited to suggest additional outcomes
which they considered to be important. Outcomes sug-
gested by panellists were considered for inclusion in the
second round of the questionnaire.
The Delphi panel was invited to complete the ques-
tionnaire via email; a link to the questionnaire on the
SurveyGizmo® website was provided. All respondents of
the first-round questionnaire were invited to participate
in the second-round questionnaire. The second round
included items for which no consensus had been
reached in the first round (see ‘Data analysis’ section)
and any new outcomes suggested by panellists in the
first round. A personalised summary of the first-round
scores (individual score, group mean score, group
median score) for each outcome was sent with the email
invitation for the second questionnaire round. The Delphi
panel was instructed to consider the feedback provided
whilst re-scoring the outcomes contained in the second-
round questionnaire. For both rounds, reminder emails
were sent as necessary to encourage participation, and a
deadline of 4 weeks was given for completion.
Data analysis
The Delphi survey responses were analysed using SPSS
22.0. For each outcome, the group mean and median
scores were calculated for the feedback purposes de-
scribed above. The round 1 questionnaires were analysed
by calculating the percentage of participants rating each
outcome as critically important (i.e. 7, 8 or 9) and not
important (i.e. 1, 2 or 3). Consensus for an outcome be-
ing included in the COS was defined as ≥70% of respon-
dents scoring an outcome 7–9 and <15% scoring the
outcome 1–3. Conversely, consensus for an outcome
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being excluded from the COS was defined as ≥70% of
respondents scoring an outcome 1–3 and <15% scoring
the outcome 7–9. All other score distributions indicated
that no consensus was achieved for the outcome [1].
Only those outcomes from round 1 for which no con-
sensus was achieved following analysis of the round 1
results were retained for the round 2 questionnaire.
Round 2 responses were analysed by applying the same
consensus criteria as in round 1. Outcomes for which no
consensus was achieved following the second round of
the questionnaire were not included in the final COS.
In order to construct the final COS, the outcomes
retained following both rounds of the Delphi exercise
were organised under a hierarchy of outcome domains
and categories [26] created by the grouping together of
any closely related, overlapping but distinct individual
outcomes. The classification of outcomes into domains
and categories was achieved via discussion between
three of the authors (AM, CH and DA).
Results
In Phase 1, a total of 63 outcomes for potential inclusion
in the COS were identified (22 from 12 studies included
in the Cochrane systematic review and 41 from the
stakeholder focus groups and interviews). The demog-
raphy of the different stakeholders (n = 85) involved in
identifying outcomes during the course of the interviews
and focus groups is shown in Table 1.
Of the 63 outcomes, 16 duplicates (i.e. outcomes
which were identified in both the literature and also
reported by the stakeholders) were removed as were 16
process measures. Examples of process measures that
were removed included: ‘satisfaction with PIP service’
and ‘care home staff ’s accuracy of record keeping’.
Additionally, a unanimous decision was reached by the
chosen four members of the CHIPPS team to exclude
two outcomes (‘pain’ and ‘accidents’) from the Delphi
exercise. This review and refinement therefore resulted
in a total of 29 outcomes going forward to the first
round of the Delphi questionnaire (see Fig. 1).
Delphi consensus exercise
All 19 Delphi panellists completed the first round of the
Delphi questionnaire (100.0% response rate). Following
analysis, 12 outcomes met the consensus criteria for in-
clusion in the COS. No outcomes met the consensus
criteria for exclusion from the COS; no consensus was
achieved for 17 outcomes (see Table 2).
When asked if they wished to suggest any further out-
comes that they thought should be included in the COS,
in total, three participants suggested: ‘patient mobility’,
‘making sure drug charts are kept up to date’, ‘anticholiner-
gic burden’, ‘nutritional status’, e.g. MUST (Malnutrition
Universal Screening Tool) score, or ‘use of nutrition sup-
plements’ and ‘appropriate use of covert medication’. Fol-
lowing discussion of these suggested items amongst three
of the authors (AM, CH and DA), one new outcome
(‘anticholinergic burden’) was added to the list for inclu-
sion in the second round of the Delphi questionnaire. ‘Pa-
tient mobility’ was considered to be encompassed within
the outcome ‘physical functioning’ and was not added.
The other suggestions were not considered relevant for
studies aiming to optimise prescribing (of medicines) in
care homes and were therefore also not included.
In addition, feedback from one Delphi panel participant
led to the re-formulation of the outcome ‘number of med-
icines (and associated costs)’ to two separate outcomes:
‘number of medicines’ and ‘costs of medicines’. As such,
these two outcomes, along with anticholinergic burden
and the 17 outcomes carried forward from round 1, re-
sulted in a total of 20 outcomes being included in the sec-
ond round of the Delphi questionnaire (see Fig. 1).
Eighteen of the 19 round 1 respondents completed
round 2 (94.7% response). Two further outcomes (‘num-
ber of medicines’ and ‘anticholinergic burden’) met the
criteria for consensus inclusion in the COS (see Table 3).
Therefore, a total of 13 individual outcomes met the
criteria for inclusion in the COS following both rounds
of the Delphi exercise. These 13 outcomes were grouped
into a total of seven distinct outcome domains, which
were then organised under three overarching categories
of outcomes: medication-related, patient-related and
healthcare utilisation-related outcomes (Table 4).
Discussion
This study used a comprehensive approach involving
an up-to-date systematic literature review, stakeholder
involvement and formal consensus methodology to
Table 1 Stakeholder-specific focus groups and interviews
UK site Number of
focus groups
Participant type
and numbers
Number of
interviews
Participant
type
A 3 Pharmacists × 4
GPs × 5 Residents/
relatives × 8
2 Pharmacist
× 1 GP × 1
B 3 Pharmacists × 8 GPs
× 10 Care
home staff × 2
4 GP × 1
Care home
staff × 3
C 5 Pharmacists × 8
GPs × 7 Care
home staff × 4
Care home
managers × 3
Residents/
relatives × 6
0 NA
D 2 Pharmacists × 5
GPs × 2
7 Pharmacist ×
1 GPs × 3
Care home
managers × 3
Total 13 72 participants 13 13 participants
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develop a COS for effectiveness studies aimed at
optimising prescribing in older adults in care homes.
The final COS comprises 13 outcomes, arranged
under seven broader outcome domains: medication
appropriateness (potentially inappropriate prescribing),
adverse drug events, prescribing errors, falls, quality
of life, all-cause mortality and admissions to hospital
(and associated costs). It is recommended that this
COS be used to guide outcome selection in future
studies conducted in this research area.
The outcomes contained in this COS have been
derived from both the published literature and the input
of a large, wide-ranging number of relevant stakeholders,
including healthcare professionals and service users/their
relatives. Furthermore, the outcomes selected for inclu-
sion in the final COS have been rated as critically
important by a panel of experts in the field. It is evident
that there is a relationship between the seven overarch-
ing outcome domains that comprise this COS. Inappro-
priate prescribing of medicines, which may be the result
of errors in prescribing [27], is known to be associated
with an increased risk of adverse drug events (ADEs)
[28]. Furthermore, ADEs are frequently a causative or
contributory factor to hospitalisation in older adults
[29]. Anticholinergic burden, a measure of a patient’s
cumulative exposure to medicines with anticholinergic
properties, has been shown to be associated with an
increased risk of hospitalisation for confusion or demen-
tia [30]. Falls, which may also be a manifestation of an
ADE, are of particular concern amongst institutionalised
older adults, as they are directly responsible for signifi-
cant morbidity and mortality in this population [31].
Additionally, quality of life (QoL) is an important target
for interventions, as the loss of personal independence
and the frailty which characterises the care home popu-
lation means it is an outcome of particular significance
[32]. Whilst interventions to optimise prescribing often
are primarily focussed on improving healthcare system-
related outcomes (e.g. hospitalisations), it is important
that researchers in the future also focus on patient-
centred outcomes, including QoL.
This study has several strengths in its design and
conduct. We have followed the guidelines for COS de-
velopment, as outlined by the COMET Initiative [1].
This study used multiple comprehensive approaches to
identify outcomes for potential inclusion in the COS.
Fig. 1 COS development overview
Millar et al. Trials  (2017) 18:175 Page 6 of 12
Only those studies with randomised controlled designs
were included in the systematic review that was subse-
quently used to generate the long-list of outcomes. It is
therefore possible that had the literature search criteria
been expanded to include other study designs, further
outcomes may have been identified for potential inclu-
sion in the COS. However, the review was not the sole
means of identifying potential outcomes, as opportun-
ities were provided for stakeholders to suggest outcomes
of importance to them. Relevant stakeholders, including
care home residents and their relatives as well as health-
care professionals, were actively involved in identifying
outcomes of importance to them. Involving service users
and/or their representatives is encouraged in the field of
COS development, as these individuals may identify
outcomes of importance that may not otherwise be
identified in the published literature or by other stake-
holders, such as healthcare professionals [13, 33, 34].
Table 2 Delphi questionnaire round 1 results
Outcome Mean Delphi
score
Median
Delphi score
Respondents scoring 7–9
‘critically important’ (%)
Respondents scoring 1–3
‘not important’ (%)
Result
(In, Out, No consensus)
Number of medications (and associated
costs)
7.7 8.5 83.3 0 In
Medication wastage (and associated
costs)
6.6 7 68.4 10.5 No consensus
Polypharmacy (≥4 medicines) 6.5 7 57.9 10.5 No consensus
Medication appropriateness (potentially
inappropriate prescribing)
8.2 9 84.2 0 In
Duplicate drugs 7.2 7.5 72.2 5.6 In
Use of antipsychotics 7.4 8 73.7 0 In
Medication changes made (by anyone) 6.9 8 63.2 10.5 No consensus
Number of medication reviews
conducted (by anyone)
6.7 7 63.2 10.5 No consensus
Admissions to hospital (and associated
costs)
8.2 8 100 0 In
Accident and emergency (A&E) visits (and
associated costs)
7.8 8 83.3 0 In
Visits to outpatients (and associated
costs)
5.3 5 26.3 31.6 No consensus
Visits to/from GP (and associated costs) 7.1 7 63.2 5.3 No consensus
Visits to/from nurse (and associated costs) 6.1 6 42.1 5.3 No consensus
Adverse drug events 8.4 9 94.7 0 In
Falls 7.4 7 84.2 0 In
Acute kidney injury 6.7 6 46.7 0 No consensus
Prescribing errors 7.9 8 89.5 5.3 In
Harmful interactions 7.7 8 84.2 5.3 In
All-cause mortality 7.5 9 78.9 5.3 In
Physical functioning 6.5 7 57.9 15.8 No consensus
Behaviour 6.6 7 63.2 5.3 No consensus
Cognitive functioning 6.6 7 57.9 5.3 No consensus
Depression 6.3 7 55.6 5.6 No consensus
Quality of life 7.7 8 83.3 0 In
Compliance with NICE guidelines 6.3 7 52.6 10.5 No consensus
Compliance with medicines 6.7 7 68.4 5.3 No consensus
Care home staff job satisfaction 5 5 26.3 36.8 No consensus
Efficiency of medication administration by
care home staff
6.3 6 42.1 5.3 No consensus
Accuracy of administration of
medications by care home staff
6.9 7 57.9 5.3 No consensus
NICE National Institute for Health and Care Excellence
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Furthermore, the relative importance placed on various
outcomes can often differ between patients, service users
and healthcare professionals [35, 36]. The inclusion of
key stakeholder groups throughout the development of
this COS was an intentional effort to maximise its rele-
vance to these groups and therefore its acceptance in
future research.
This study employed a well-established and widely
used method of achieving consensus in order to facilitate
the inclusion of a broad range of panel participants in
geographically diverse locations. The Delphi consensus
technique has been frequently employed by other COS
developers as a means of reaching consensus [37–39].
As individuals participating in the Delphi exercise need
not directly interact with each other, this consensus
technique has the advantage of preventing bias resulting
from more vocal or senior panellists dominating the
views of the group, which is more likely in a face-to-face
setting [36]. Furthermore, the online administration of
Delphi questionnaires avoids the logistical, practical and
economic challenges typically associated with postal
questionnaires or face-to-face meetings [40]. Therefore,
whilst this consensus method was considered appropri-
ate for use for the above reasons, an alternative method
may have led to a different final set of outcomes. The
response rates for the questionnaire were 100% and
94.7% for rounds 1 and 2, respectively. This low rate of
attrition may reflect the composition of the Delphi panel
from members of the wider study team.
The main limitation of this study is that all the Delphi
panel participants were from the UK, which may affect
the wider generalisability of the results. It is possible that
a larger, international Delphi panel may have produced a
different COS, as certain outcomes could be valued
differently in other countries. The widespread adoption
and reporting of outcomes contained in this COS in
future studies would aid in its validation outside of the
UK setting. Another possible limitation is that there
were no pre-specified proportions of the various groups
of individuals (i.e. doctors, PPI representatives, etc.) who
comprised the Delphi panel. Previous COS developers
have recruited patients and professionals to their Delphi
panels in a 2:1 ratio, to give preference to patient-
reported outcomes [37, 41]. Therefore, it is possible that
some outcomes may not have met the consensus criteria
for inclusion as a result of under-representation of a
particular stakeholder group.
Unlike previous COS developers [37, 39, 41], we did
not implement a ‘consensus meeting’ following the
Delphi exercise. The decision not to include a consensus
Table 3 Delphi questionnaire round 2 results
Outcome Mean Med Respondents scoring 7–9
‘critically important’ (%)
Respondents scoring 1–3
‘not important’ (%)
Consensus Result
(In, Out, No consensus)
Number of medications 7.3 8.0 83.3 11.1 In
Costs of prescribed medications 6.3 7.0 61.1 11.1 No consensus
Medication wastage (and associated costs) 6.6 7.0 66.7 5.6 No consensus
Polypharmacy (≥4 medicines) 6.6 7.0 66.7 5.6 No consensus
Medication changes made (by anyone 6.5 7.0 55.6 5.6 No consensus
Number of medication reviews conducted (by anyone) 6.6 7.0 66.7 5.6 No consensus
Visits to outpatients (and associated costs) 5.6 5.0 33.3 5.6 No consensus
Visits to/from GP (and associated costs) 6.6 6.5 50.0 0 No consensus
Visits to/from nurse (and associated costs) 6.1 6.5 50.0 0 No consensus
Acute kidney injury 6.8 7.0 53.3 0 No consensus
Physical functioning 6.5 7.0 61.1 5.6 No consensus
Behaviour 6.9 7.0 61.1 5.6 No consensus
Cognitive functioning 6.8 7.0 61.1 0 No consensus
Depression 6.7 7.0 61.1 0 No consensus
Compliance with NICE guidelines 6.4 7.0 55.6 16.7 No consensus
Compliance with medicines 6.9 7.5 61.1 5.6 No consensus
Care home staff job satisfaction 5.1 5.0 22.2 5.6 No consensus
Efficiency of medication administration by care
home staff
6.4 6.0 38.9 0 No consensus
Accuracy of administration of medications by care home
staff
7.3 7.0 55.6 0 No consensus
Anticholinergic burden 7.3 7.0 75.0 0 In
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meeting in the COS development process was a prag-
matic one. Holding a final consensus meeting to make
decisions on whether the ‘undecided’ outcomes should
be included in the final COS may have resulted in a
larger final COS. However, it should be noted that
consensus had been reached for 13 outcomes (seven
outcome domains) following the two planned rounds of
the Delphi. It is important to bear in mind that a COS
represents a minimum number of outcomes that, ideally,
should be measured in all trials in a specific area;
additional outcomes can be freely included if deemed
relevant [4].
In this study, outcomes that had not achieved consen-
sus support following the second round of the Delphi
were excluded from the COS, despite not having met
the pre-defined consensus criteria for exclusion. It is
possible that further Delphi rounds may have achieved
consensus on more outcomes; however, due to time
restraints and a pre-defined Delphi of two rounds, this
was not possible. There are currently no guidelines for
Table 4 Final COS for effectiveness studies in optimising prescribing in older adults in care homes
Category Outcome domain
• Outcome
Definition from Delphi questionnaire
Medication-related 1. Medication appropriateness
(potentially inappropriate prescribing)
Potentially inappropriate prescribing ‘encompasses the use of medicines that introduce
a significant risk of an adverse drug-related event where there is evidence for an
equally or more effective but lower-risk alternative therapy available for treating the
same condition…also includes the use of medicines at a higher frequency and for
longer than clinically indicated, the use of multiple medicines that have recognised
drug-drug interactions and drug-disease interactions, and importantly, the under-use
of beneficial medicines that are clinically indicated but not prescribed for ageist or
irrational reasons’ [53]
• Number of prescribed medicines Number of medications prescribed for a care home resident
• Duplicate drugs ’Duplicate drugs’ described a situation where an individual is prescribed two
medicines of the same pharmacological class, e.g. the prescribing of two
concurrent opiates [54]
• Use of antipsychotics The prescription of antipsychotic medicines in care home residents. ‘Antipsychotic
drugs are also known as “neuroleptics” and (misleadingly) as “major tranquillisers”. In
the short term they are used to calm disturbed patients whatever the underlying
psychopathology… The balance of risks and benefits should be considered before
prescribing antipsychotic drugs for elderly patients’ [55]
• Harmful interactions A ‘harmful interaction’ in a care home resident may describe the prescription of a
medication which causes or has the potential to cause a clinically significant drug-
drug or drug-disease interaction. A drug-drug interaction is when a medicine affects
the pharmacological effect of another medicine. A drug-disease interaction is when a
medicine, which may be used to treat or prevent one disease, can have a detrimental
effect on another existing disease/condition in the individual [56]
• Anticholinergic burden The anticholinergic burden associated with care home residents’ medication regimens.
Medicines with anticholinergic effects are commonly prescribed for various conditions;
however, increased overall exposure to anticholinergics has been associated with an
increased risk of cognitive impairment, falls and all-cause mortality in older adults [57]
2. Adverse drug events Adverse drug events experienced by care home residents. ‘An adverse drug event is
any undesirable event experienced by a patient whilst taking a medicine, including
physical harm, mental harm, or loss of function’ [58]
3. Prescribing errors Prescribing errors in care home residents’ medication regimens. A prescribing error is
‘a prescribing decision that results in an unintentional, significant: (1 reduction in the
probability of treatment being timely and effective, or (2 Increase in the risk of harm,
when compared to generally accepted practice’ [59]
Patient-related 4. Falls Falls occurring amongst care home residents. A fall is ‘an event which results in a
person coming to rest inadvertently on the ground or floor or other lower level’ [60]
5. Quality of life A measure of care home residents’ quality of life (QoL). QoL is ‘a ubiquitous concept
that has different philosophical, political and health-related definitions. Health-related
QoL includes the physical, functional, social and emotional well-being of an
individual’ [61]
6. All-cause mortality All deaths of care home residents
Healthcare
utililisation-related
7. Admissions to hospital
(and associated costs)
The number of care home residents having a hospital admission/number of hospital
admissions per resident (and the associated costs)
• Accident and emergency (A&E) visits
to hospital (and associated costs)
The number of care home residents attending A&E departments/number of A&E visits
per resident (and the associated costs)
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the most appropriate number of Delphi rounds to be
conducted. It is therefore recommended that future
COS developers give consideration as to how they will
deal with ‘undecided outcomes’ following the final round
of a Delphi questionnaire, should they choose not to in-
clude a final face-to-face consensus meeting as part of
the process. It may also be worthwhile to ask partici-
pants to provide a rationale for each of their scores in
the first round. Such information could then be collated
and presented alongside the group score feedback to all
participants, in order to inform individuals’ judgements
in the second round of scoring the outcomes, thus facili-
tating group consensus.
It is important to note that the proposed COS has
been developed to guide researchers on what to meas-
ure. The COS does not indicate how (or when) to meas-
ure and report these outcomes in a study. Of the 12
studies included in the systematic review from which
outcomes were identified for potential inclusion in this
COS, five studies measured medication appropriateness
as an outcome. Across these five studies alone, three
different tools were used to measure ‘medication appro-
priateness’ as an outcome: Screening Tool of Older
People’s Prescriptions/Screening Tool to Alert doctors
to Right Treatment (STOPP/START) [42], the Medica-
tion Appropriateness Index (MAI) [43] and a modified
version of the Beers Criteria [44]. Similarly, in the two
papers included in the review that measured and
reported QoL as an outcome, two different measure-
ment tools were used: the 15D [45] and the 12-Item
Short-Form Health Survey (SF-12) [46]. Many more
measurement tools exist to measure both these, and
other, outcomes, including those outcomes suggested by
stakeholders, such as ‘anticholinergic burden’, which can
be quantified with a number of different tools including
the Drug Burden Index [47] and the Anticholinergic
Cognitive Burden Scale [48]. A detailed review or
recommendation on the instruments to be used to meas-
ure the outcomes included in this COS, including medica-
tion appropriateness, QoL and anticholinergic burden, is
beyond the scope of this paper and a current limitation of
COSs in general.
Nonetheless, determining the most appropriate methods
of measuring the outcomes in this COS will be crucial for
its widespread acceptance and usefulness. In order to
reduce heterogeneity in outcome measurement between
trials, the next step will therefore be to determine how
outcomes included in this COS should ideally be
measured. Guidelines on how to select outcome measure-
ment instruments are currently being developed by the
Core Outcome Measurement Instrument Selection
(COMIS) project group [49]. It is possible that this COS
may highlight the absence of appropriate outcome meas-
urement instruments, either because no instrument exists
to measure the outcome or because the evidence base for
existing measurement instruments is of limited quality.
Furthermore, where several instruments all purporting to
measure the same outcome exist, it may not be clear
which instrument would be most appropriate. The COS-
MIN (Consensus-based Standards for the selection of
health Measurement Instruments) checklist can be used
to evaluate the methodological quality of studies on meas-
urement properties (e.g. validity and reliability) and there-
fore may also be used to help inform the selection of the
most appropriate measurement instrument for an out-
come [50]. Furthermore, measurement properties includ-
ing the acceptability of the measure (e.g. for patients and
healthcare professionals) and its responsiveness to clinical
change (i.e. its sensitivity to detect meaningful change) are
also important considerations when selecting a measure-
ment instrument [51].
In line with recommendations from COMET, this COS
should be subject to review in the future as a form of val-
idation to ensure outcomes are still relevant and import-
ant. Such reviews should also facilitate the addition of new
outcomes, where necessary, through emergent evidence
and the engagement of further key stakeholders [52].
Conclusions
This work has identified a list of 13 outcomes (cate-
gorised into seven core outcome domains) to be mea-
sured and reported as a minimum in effectiveness
studies aimed at optimising prescribing in older adults
in care homes. To the authors’ best knowledge, this is
the first COS for effectiveness studies in this field. It is
recommended that this COS be reviewed periodically to
validate the continued importance and relevance of its
outcomes and to allow new outcomes to be added when
necessary [1]. The next step will be to determine how
best to measure outcomes included in this COS, so as to
facilitate evidence synthesis by reducing heterogeneity in
outcome measurement between future trials in this area.
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